Neumora Therapeutics: Buy Rating Backed by De-Risked NMRA-215 Development and Strengthening NLRP3 Class ThesisTip Ranks·Jul 27 at 09:55 AMNMRA-2.44%
Neumora Therapeutics posts corporate presentation on neuroscience drug development pipelinePUBT·Jul 27 at 06:03 AMNMRA-2.44%
Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026Unusual Whales·Jul 27 at 06:02 AMNMRA-2.44%
Neumora plans NMRA-215 clinical trial in 2026 after favorable toxicology resultsPUBT·Jul 27 at 06:00 AMNMRA-2.44%
Siren L.L.C. Buys 2,209,039 Shares of Neumora Therapeutics, Inc. $NMRAMarket Beat·Jul 24 at 05:26 AMNMRA-2.44%GS-C-0.25%
Inside Blackstone’s Infrastructure Push and the Summer’s Biggest Biotech ShakeupGlobal Report·Jul 14 at 06:47 AMMOG.A+3.26%SA+3.22%
Datadog, EHang Holdings And Other Big Stocks Moving Lower In Monday’s Pre-Market Sessionbenzinga_article·Jul 6 at 07:02 AMDDOG+5.32%CNCK-7.59%
U.S. stock night market volatility: Neumora fell 3.27% in after-hours trading: core drug pipeline failure, target price halvedPrice Alert·Jun 17 at 09:31 PMNMRA-2.44%
NMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law ViolationsPR Newswire·Jun 17 at 08:07 AMNMRA-2.44%
12 Health Care Stocks Moving In Tuesday's After-Market Sessionbenzinga_article·Jun 16 at 04:06 PMNMRA-2.44%ADTX0.00%
16:44 ETNeumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)prnewswire·Jun 16 at 03:45 PMNMRA-2.44%
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga_article·Jun 16 at 12:06 PMCUPR+2.77%RGNT+10.16%
